Stefania Barruscotti

Medicine & Life Sciences

1. Melanoma 100%
2. Registries 74%
3. Skin 65%
4. Survival 53%
5. Immunotherapy 36%
6. Erythema 27%
7. Therapeutics 27%
8. Italy 26%
9. Omalizumab 19%
10. Dermatology 18%
11. Alopecia Areata 18%
12. pembrolizumab 17%
13. Ipilimumab 17%
14. Ants 17%
15. Bullous Pemphigoid 17%
16. Mycosis Fungoides 17%
17. Nivolumab 17%
18. Pemphigus 16%
19. Coronavirus 16%
20. Pandemics 16%
21. Photochemotherapy 15%
22. Celiac Disease 14%
23. Bites and Stings 14%
24. Rituximab 14%
25. Mitogen-Activated Protein Kinase Kinases 14%
26. Literature 14%
27. B-Cell Lymphoma 13%
28. Biological Products 13%
29. Skin Neoplasms 13%
30. Brown Recluse Spider 12%
31. Retrospective Studies 11%
32. Guidelines 11%
33. Proportional Hazards Models 11%
34. Clinical Trials 10%
35. Adrenal Cortex Hormones 10%
36. Hospital Emergency Service 10%
37. Emergencies 10%
38. Referral and Consultation 9%
39. Dermatitis Herpetiformis 9%
40. Neoplasms 9%
41. Cutaneous T-Cell Lymphoma 9%
42. Spiders 9%
43. Cross-Sectional Studies 8%
44. Health Care Outcome Assessment 8%
45. Infections 6%
46. Disease Progression 6%
47. Pharmaceutical Preparations 6%
48. Child 5%
49. Skin Diseases 5%
50. Lymphangitis 5%